Kala Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Kala Pharmaceuticals's estimated annual revenue is currently $11.6M per year.
- Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
- Kala Pharmaceuticals's estimated revenue per employee is $122,316
- Kala Pharmaceuticals's total funding is $506.4M.
- Kala Pharmaceuticals's current valuation is $66.2M. (January 2022)
Employee Data
- Kala Pharmaceuticals has 95 Employees.
- Kala Pharmaceuticals grew their employee count by 2% last year.
Kala Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman/CEO | Reveal Email/Phone |
2 | Head R&D and Chief Medical Officer | Reveal Email/Phone |
3 | President & Chief Operating Officer | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | VP Pre-Clinical R&D | Reveal Email/Phone |
6 | VP, Biologics R&D | Reveal Email/Phone |
7 | Associate Director, Quality Operations | Reveal Email/Phone |
8 | Director | Reveal Email/Phone |
9 | Executive Director | Reveal Email/Phone |
10 | Senior Director, Finance, Reporting and Controls | Reveal Email/Phone |
Kala Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 340 | 0% | $634M | N/A |
#2 | $57.9M | 288 | 0% | N/A | N/A |
#3 | $2M | 10 | -17% | N/A | N/A |
#4 | $33.6M | 167 | 20% | N/A | N/A |
#5 | $15.5M | 77 | 126% | N/A | N/A |
#6 | $25.1M | 125 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.1M | 50 | -2% | N/A | N/A |
#9 | $1.8M | 385 | -4% | $538M | N/A |
#10 | $46.6M | 232 | -7% | N/A | N/A |
What Is Kala Pharmaceuticals?
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power
$506.4M
Total Funding
95
Number of Employees
$11.6M
Revenue (est)
2%
Employee Growth %
$66.2M
Valuation
N/A
Accelerator
Kala Pharmaceuticals News
InvestorsObserver is giving Kala Pharmaceuticals Inc (KALA) an Analyst Rating Rank of 27, meaning KALA is ranked higher by analysts than 27%...
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for...
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update. Published: Mar 29, 2022. -- Achieved $11.2...
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of ...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to init ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.8M | 96 | -3% | N/A |
#2 | $19.9M | 99 | 8% | N/A |
#3 | $15.5M | 100 | N/A | $400M |
#4 | $15.7M | 101 | 2% | $170M |
#5 | $15.7M | 101 | 31% | $7.7M |
Kala Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-03-15 | $6.2M | Undisclosed | Lux Capital, Polaris Venture Partners | Article |
| 2013-03-01 | $11.5M | A | Crown Venture Fund LLC | Article |
| 2014-04-24 | $22.5M | B | Ysios Capital | Article |
| 2016-04-14 | $68.0M | C | Longitude Capital | Article |
| 2018-10-03 | $110.0M | Undisclosed | Athyrium Capital Management | Article |